Home

tanzen Enorme Katalog dlt dose schön redaktionell Laufend

Cancers | Free Full-Text | Phase I Dose Escalation Study with Expansion  Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin  (CapOx) as First-Line Treatment of Metastatic Esophagogastric  Adenocarcinoma (ACTION Study)
Cancers | Free Full-Text | Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)

A hybrid design for dose‐finding oncology clinical trials - Liao - 2022 -  International Journal of Cancer - Wiley Online Library
A hybrid design for dose‐finding oncology clinical trials - Liao - 2022 - International Journal of Cancer - Wiley Online Library

Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule
Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule

On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and  Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse  Events (CTCAE)
On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse Events (CTCAE)

Frontiers | A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin  in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal  Chemotherapy
Frontiers | A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy

A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3-  or 24-Hour Infusion in Older Patients with Previously Untreated Acute  Myeloid Leukemia | PLOS ONE
A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia | PLOS ONE

Illustration of the chronic dose-limiting toxicity (DLT) concept. (*)... |  Download Scientific Diagram
Illustration of the chronic dose-limiting toxicity (DLT) concept. (*)... | Download Scientific Diagram

Study design for dose-escalation cohorts and DLT rate (as calculated by...  | Download Scientific Diagram
Study design for dose-escalation cohorts and DLT rate (as calculated by... | Download Scientific Diagram

Innovative design for a phase 1 trial with intra-patient dose escalation:  The Crotoxin study - ScienceDirect
Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study - ScienceDirect

Dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) in Phase... |  Download Table
Dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) in Phase... | Download Table

Bayesian Optimal Interval Design: A Simple and Well-Performing Design for  Phase I Oncology Trials. - Abstract - Europe PMC
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. - Abstract - Europe PMC

Determining drug dose in the era of targeted therapies: playing it  (un)safe? | Blood Cancer Journal
Determining drug dose in the era of targeted therapies: playing it (un)safe? | Blood Cancer Journal

Study protocol: phase 1 dose escalating study of Pressurized  Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in  peritoneal metastasis
Study protocol: phase 1 dose escalating study of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis

Biostatistical intepretation series II Clinical Trials Phase I - mitigating  misinterpretation risk in dose escalation studies
Biostatistical intepretation series II Clinical Trials Phase I - mitigating misinterpretation risk in dose escalation studies

On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and  Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse  Events (CTCAE)
On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse Events (CTCAE)

Dose levels, enrollment, and DLT in days 1-42 | Download Table
Dose levels, enrollment, and DLT in days 1-42 | Download Table

Recommended dosages in each arm. DLT, dose-limiting toxicity; RD,... |  Download Scientific Diagram
Recommended dosages in each arm. DLT, dose-limiting toxicity; RD,... | Download Scientific Diagram

Exposure driven dose escalation design with overdose control: Concept and  first real life experience in an oncology phase I trial - ScienceDirect
Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial - ScienceDirect

Safety and tolerability of bosutinib in patients with amyotrophic lateral  sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase  1 trial - eClinicalMedicine
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial - eClinicalMedicine

Innovative design for a phase 1 trial with intra-patient dose escalation:  The Crotoxin study. - Abstract - Europe PMC
Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study. - Abstract - Europe PMC

Adaptive design for identifying maximum tolerated dose early to accelerate  dose-finding trial | BMC Medical Research Methodology | Full Text
Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial | BMC Medical Research Methodology | Full Text

Principles of dose finding studies in cancer: a comparison of trial designs  | Cancer Chemotherapy and Pharmacology
Principles of dose finding studies in cancer: a comparison of trial designs | Cancer Chemotherapy and Pharmacology

1. In a typical Phase I clinical trial of a new drug, | Chegg.com
1. In a typical Phase I clinical trial of a new drug, | Chegg.com